Pathophysiological implications of insulin resistance on vascular endothelial function
暂无分享,去创建一个
[1] M. Shichiri,et al. Bradykinin enhances GLUT4 translocation through the increase of insulin receptor tyrosine kinase in primary adipocytes: evidence that bradykinin stimulates the insulin signalling pathway , 1996, Diabetologia.
[2] G. Paolisso,et al. Oxidative stress and insulin action: is there a relationship? , 1996, Diabetologia.
[3] H. Yki-Järvinen. Insulin resistance and endothelial dysfunction. , 2003, Best practice & research. Clinical endocrinology & metabolism.
[4] D. Heymann,et al. Deadly comrades: war and infectious diseases , 2002, The Lancet.
[5] AndrewJ. S. Coats. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial , 2002, The Lancet.
[6] R. Garofalo,et al. Positive and negative regulatory role of insulin receptor substrate 1 and 2 (IRS-1 and IRS-2) serine/threonine phosphorylation. , 2002, Biochemistry.
[7] A. Shah,et al. Acute haemodynamic effects of lipolysis-induced increase of free fatty acids in healthy men. , 2002, Clinical science.
[8] E. Bonora,et al. Insulin Causes Endothelial Dysfunction in Humans: Sites and Mechanisms , 2002, Circulation.
[9] A. Saltiel,et al. Insulin signaling pathways in time and space. , 2002, Trends in cell biology.
[10] W. Dietz,et al. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. , 2002, JAMA.
[11] A. Coats. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20 536 high-risk individuals: a randomised placebo-controlled trial , 2002 .
[12] H. Gavras,et al. Role of the B2 Receptor of Bradykinin in Insulin Sensitivity , 2001, Hypertension.
[13] Margaret S. Wu,et al. Role of AMP-activated protein kinase in mechanism of metformin action. , 2001, The Journal of clinical investigation.
[14] A. Marette,et al. Targeted disruption of inducible nitric oxide synthase protects against obesity-linked insulin resistance in muscle , 2001, Nature Medicine.
[15] Y. Kaneda,et al. Leptin Induces Mitochondrial Superoxide Production and Monocyte Chemoattractant Protein-1 Expression in Aortic Endothelial Cells by Increasing Fatty Acid Oxidation via Protein Kinase A* , 2001, The Journal of Biological Chemistry.
[16] D. Webb,et al. Activation of the endothelin system in insulin resistance. , 2001, QJM : monthly journal of the Association of Physicians.
[17] D. Weiss,et al. Angiotensin II and atherosclerosis. , 2001, The American journal of cardiology.
[18] K. Kamata,et al. Effect of chronic insulin treatment on NO production and endothelium-dependent relaxation in aortae from established STZ-induced diabetic rats. , 2001, Atherosclerosis.
[19] K. Mather,et al. Improved endothelial function with metformin in type 2 diabetes mellitus. , 2001, Journal of the American College of Cardiology.
[20] R. Schmieder,et al. Rapid improvement of nitric oxide bioavailability after lipid-lowering therapy with cerivastatin within two weeks. , 2001, Journal of the American College of Cardiology.
[21] John P H Wilding,et al. Troglitazone corrects metabolic changes but not vascular dysfunction in dietary-obese rats. , 2001, European journal of pharmacology.
[22] É. Hajduch,et al. Protein kinase B (PKB/Akt) – a key regulator of glucose transport? , 2001, FEBS letters.
[23] Bruce M. Spiegelman,et al. Obesity and the Regulation of Energy Balance , 2001, Cell.
[24] A. Saltiel. New Perspectives into the Molecular Pathogenesis and Treatment of Type 2 Diabetes , 2001, Cell.
[25] R. Paschke,et al. Plasma levels of tumor necrosis factor-alpha, angiotensin II, growth hormone, and IGF-I are not elevated in insulin-resistant obese individuals with impaired glucose tolerance. , 2001, Diabetes care.
[26] D. Stewart,et al. Endothelin Antagonism Uncovers Insulin-Mediated Vasorelaxation In Vitro and In Vivo , 2001, Hypertension.
[27] T. Rabelink,et al. Cellular regulation of endothelial nitric oxide synthase. , 2001, American journal of physiology. Renal physiology.
[28] A. M. Lefer,et al. Vascular effects of HMG CoA-reductase inhibitors (statins) unrelated to cholesterol lowering: new concepts for cardiovascular disease. , 2001, Cardiovascular research.
[29] P W Macfarlane,et al. Pravastatin and the Development of Diabetes Mellitus: Evidence for a Protective Treatment Effect in the West of Scotland Coronary Prevention Study , 2001, Circulation.
[30] M. Lazar,et al. The hormone resistin links obesity to diabetes , 2001, Nature.
[31] J. Mckenney,et al. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). , 2001, JAMA.
[32] C. Kahn,et al. Unraveling the mechanism of action of thiazolidinediones. , 2000, The Journal of clinical investigation.
[33] B. Winters,et al. Reduction of obesity, as induced by leptin, reverses endothelial dysfunction in obese (Lep(ob)) mice. , 2000, Journal of applied physiology.
[34] D. Harrison,et al. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. , 2000, Circulation research.
[35] T. Lüscher,et al. Endothelins and Endothelin Receptor Antagonists: Therapeutic Considerations for a Novel Class of Cardiovascular Drugs , 2000, Circulation.
[36] D. Green,et al. Losartan, an angiotensin type 1 receptor antagonist, improves endothelial function in non-insulin-dependent diabetes. , 2000, Journal of the American College of Cardiology.
[37] H. Utsumi,et al. High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C--dependent activation of NAD(P)H oxidase in cultured vascular cells. , 2000, Diabetes.
[38] M. Quon,et al. Insulin action in vascular endothelium: potential mechanisms linking insulin resistance with hypertension , 2000, Diabetes, obesity & metabolism.
[39] H. Maegawa,et al. Oral Administration of Tetrahydrobiopterin Prevents Endothelial Dysfunction and Vascular Oxidative Stress in the Aortas of Insulin-Resistant Rats , 2000, Circulation research.
[40] M. Kanzaki,et al. CAP defines a second signalling pathway required for insulin-stimulated glucose transport , 2000, Nature.
[41] D. Hassall,et al. PPAR agonists as direct modulators of the vessel wall in cardiovascular disease , 2000, Medicinal research reviews.
[42] L. Lind,et al. The impairment in endothelial function induced by non-esterified fatty acids can be reversed by insulin. , 2000, Clinical science.
[43] T. Lüscher. Endothelial dysfunction: the role and impact of the renin-angiotensin system , 2000, Heart.
[44] K. Nakao,et al. Insulin resistance and endothelial dysfunction in smokers: effects of vitamin C. , 2000, American journal of physiology. Heart and circulatory physiology.
[45] E. Anggard,et al. Antioxidants, diabetes and endothelial dysfunction. , 2000, Cardiovascular research.
[46] J. Olefsky. Treatment of insulin resistance with peroxisome proliferator–activated receptor γ agonists , 2000 .
[47] A. Shah,et al. Molecular characterization and localization of the NAD(P)H oxidase components gp91-phox and p22-phox in endothelial cells. , 2000, Arteriosclerosis, thrombosis, and vascular biology.
[48] G. Garcı́a-Cardeña,et al. Reconstitution of an Endothelial Nitric-oxide Synthase (eNOS), hsp90, and Caveolin-1 Complex in Vitro , 2000, The Journal of Biological Chemistry.
[49] Robert Ross,et al. Reduction in Obesity and Related Comorbid Conditions after Diet-Induced Weight Loss or Exercise-Induced Weight Loss in Men , 2000, Annals of Internal Medicine.
[50] I. Nishio,et al. Involvement of nitric oxide in endothelium-dependent arterial relaxation by leptin. , 2000, Biochemical and biophysical research communications.
[51] L. Monti,et al. Relationship between endothelin-1 concentration and metabolic alterations typical of the insulin resistance syndrome. , 2000, Metabolism: clinical and experimental.
[52] T. Inoue,et al. Insulin resistance affects endothelium-dependent acetylcholine-induced coronary artery response. , 2000, European heart journal.
[53] G. Riccardi,et al. Dietary treatment of the metabolic syndrome — the optimal diet , 2000, British Journal of Nutrition.
[54] S. Engeli,et al. Physiology and pathophysiology of the adipose tissue renin-angiotensin system. , 2000, Hypertension.
[55] K. Channon,et al. Vascular superoxide production by NAD(P)H oxidase: association with endothelial dysfunction and clinical risk factors. , 2000, Circulation research.
[56] J. Connell,et al. Trandolapril does not improve insulin sensitivity in patients with hypertension and type 2 diabetes: a double-blind, placebo-controlled crossover trial. , 2000, The Journal of clinical endocrinology and metabolism.
[57] J. Connell,et al. Endothelial dysfunction as a possible link between C-reactive protein levels and cardiovascular disease. , 2000, Clinical science.
[58] A M Zeiher,et al. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. , 2000, Circulation.
[59] J. W. Meyer,et al. A central role for the endothelial NADPH oxidase in atherosclerosis , 2000, FEBS letters.
[60] S. Jacob,et al. Endothelial dysfunction is detectable in young normotensive first-degree relatives of subjects with type 2 diabetes in association with insulin resistance. , 2000, Circulation.
[61] M. Quon,et al. Roles for insulin receptor, PI3-kinase, and Akt in insulin-signaling pathways related to production of nitric oxide in human vascular endothelial cells. , 2000, Circulation.
[62] W. Goettsch,et al. Endothelin-1 induces NAD(P)H oxidase in human endothelial cells. , 2000, Biochemical and biophysical research communications.
[63] D. Sorescu,et al. NAD(P)H oxidase: role in cardiovascular biology and disease. , 2000, Circulation research.
[64] J. Jukema,et al. Not acute but chronic hypertriglyceridemia is associated with impaired endothelium-dependent vasodilation: reversal after lipid-lowering therapy by atorvastatin. , 2000, Arteriosclerosis, thrombosis, and vascular biology.
[65] G. King,et al. Regulation of endothelial constitutive nitric oxide synthase gene expression in endothelial cells and in vivo : a specific vascular action of insulin. , 2000, Circulation.
[66] C. Kahn,et al. Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle. , 2000, The Journal of clinical investigation.
[67] J. Westerbacka,et al. Insulin therapy improves endothelial function in type 2 diabetes. , 2000, Arteriosclerosis, thrombosis, and vascular biology.
[68] I. Keber,et al. Physical training improves flow-mediated dilation in patients with the polymetabolic syndrome. , 2000, Arteriosclerosis, thrombosis, and vascular biology.
[69] A. Zeiher,et al. Insulin-mediated stimulation of protein kinase Akt: A potent survival signaling cascade for endothelial cells. , 2000, Arteriosclerosis, thrombosis, and vascular biology.
[70] M. Laakso,et al. Insulin resistance syndrome predicts the risk of coronary heart disease and stroke in healthy middle-aged men: the 22-year follow-up results of the Helsinki Policemen Study. , 2000, Arteriosclerosis, thrombosis, and vascular biology.
[71] L. Fratta,et al. Leptin induces direct vasodilation through distinct endothelial mechanisms. , 2000, Diabetes.
[72] Bruce H. R. Wolffenbuttel,et al. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy , 2000, The Lancet.
[73] S. Yusuf,et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .
[74] S. Yusuf,et al. Vitamin E supplementation and cardiovascular events in high-risk patients. , 2000, The New England journal of medicine.
[75] A. Saltiel,et al. Signaling pathways in insulin action: molecular targets of insulin resistance. , 2000, The Journal of clinical investigation.
[76] M. Katovich,et al. Effects of inhibition of the renin‐angiotensin system on the cardiovascular actions of insulin , 2000, Diabetes, obesity & metabolism.
[77] M. Hecker,et al. Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. , 2000, Arteriosclerosis, thrombosis, and vascular biology.
[78] J. Olefsky. Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists. , 2000, The Journal of clinical investigation.
[79] J. Connell,et al. Insulin action is associated with endothelial function in hypertension and type 2 diabetes. , 2000, Hypertension.
[80] M. Hoenig,et al. Metformin improves vascular function in insulin-resistant rats. , 2000, Hypertension.
[81] C. Kahn,et al. Crosstalk between insulin and angiotensin II signalling systems. , 2009, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.
[82] A. Kashiwagi,et al. Abnormal biopterin metabolism is a major cause of impaired endothelium-dependent relaxation through nitric oxide/O2- imbalance in insulin-resistant rat aorta. , 1999, Diabetes.
[83] H. Maegawa,et al. Endothelium-specific activation of NAD(P)H oxidase in aortas of exogenously hyperinsulinemic rats. , 1999, American journal of physiology. Endocrinology and metabolism.
[84] R. Bergman,et al. Angiotensin II induces insulin resistance independent of changes in interstitial insulin. , 1999, The American journal of physiology.
[85] P. Zimmet,et al. Etiology of the Metabolic Syndrome: Potential Role of Insulin Resistance, Leptin Resistance, and Other Players , 1999, Annals of the New York Academy of Sciences.
[86] P. Strålfors,et al. Localization of the insulin receptor in caveolae of adipocyte plasma membrane , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[87] Y. Yazaki,et al. Imidapril, an angiotensin-converting enzyme inhibitor, improves insulin sensitivity by enhancing signal transduction via insulin receptor substrate proteins and improving vascular resistance in the Zucker fatty rat. , 1999, Metabolism: clinical and experimental.
[88] A. Kashiwagi,et al. Free radical production in endothelial cells as a pathogenetic factor for vascular dysfunction in the insulin resistance state. , 1999, Diabetes research and clinical practice.
[89] D. M. Rocha,et al. Overnight lowering of free fatty acids with Acipimox improves insulin resistance and glucose tolerance in obese diabetic and nondiabetic subjects. , 1999, Diabetes.
[90] M. Carrier,et al. Pro‐oxidant challenge in vivo provokes the onset of NIDDM in the insulin resistant obese Zucker rat , 1999, British journal of pharmacology.
[91] Y. Ikeda,et al. Insulin Signaling Is Inhibited by Micromolar Concentrations of H2O2 , 1999, The Journal of Biological Chemistry.
[92] R. Busse,et al. Signal transduction of eNOS activation. , 1999, Cardiovascular research.
[93] M. White,et al. Characterization of selective resistance to insulin signaling in the vasculature of obese Zucker (fa/fa) rats. , 1999, The Journal of clinical investigation.
[94] B. Mayer,et al. Enzymatic function of nitric oxide synthases. , 1999, Cardiovascular research.
[95] R. D. Rudic,et al. Molecular control of nitric oxide synthases in the cardiovascular system. , 1999, Cardiovascular research.
[96] A. Hofman,et al. Associations of C-reactive protein with measures of obesity, insulin resistance, and subclinical atherosclerosis in healthy, middle-aged women. , 1999, Arteriosclerosis, thrombosis, and vascular biology.
[97] B. Kahn,et al. Glucose transporters and insulin action--implications for insulin resistance and diabetes mellitus. , 1999, The New England journal of medicine.
[98] S. Jacob,et al. ACE inhibition and glucose transport in insulinresistant muscle: roles of bradykinin and nitric oxide. , 1999, The American journal of physiology.
[99] G. Williams,et al. The thiazolidinedione rosiglitazone (BRL-49653) lowers blood pressure and protects against impairment of endothelial function in Zucker fatty rats. , 1999, Diabetes.
[100] N. Schneiderman,et al. Is fasting leptin associated with insulin resistance among nondiabetic individuals? The Miami Community Health Study. , 1999, Diabetes care.
[101] S. Jacob,et al. ACE inhibition and glucose transport in insulinresistant muscle: roles of bradykinin and nitric oxide. , 1999, American journal of physiology. Regulatory, integrative and comparative physiology.
[102] R. Busse,et al. Leptin induces oxidative stress in human endothelial cells , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[103] K. Williams,et al. Atherosclerosis--an inflammatory disease. , 1999, The New England journal of medicine.
[104] R. Busse,et al. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation , 1999, Nature.
[105] G. Hotamisligil. The role of TNFα and TNF receptors in obesity and insulin resistance , 1999 .
[106] M. Laakso,et al. Hyperglycemia and cardiovascular disease in type 2 diabetes. , 1999, Diabetes.
[107] D. Green,et al. Improvement in endothelial function by angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. , 1999, Journal of the American College of Cardiology.
[108] M. White,et al. Endothelin-1 modulates insulin signaling through phosphatidylinositol 3-kinase pathway in vascular smooth muscle cells. , 1999, Diabetes.
[109] C. Juan,et al. Exogenous hyperinsulinemia causes insulin resistance, hyperendothelinemia, and subsequent hypertension in rats. , 1999, Metabolism: clinical and experimental.
[110] C. Kahn,et al. Protein-protein interaction in insulin signaling and the molecular mechanisms of insulin resistance. , 1999, The Journal of clinical investigation.
[111] S. Coppack,et al. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? , 1999, Arteriosclerosis, thrombosis, and vascular biology.
[112] R. Rosenson,et al. Inhibition of proinflammatory cytokine production by pravastatin , 1999, The Lancet.
[113] R. Andrade,et al. Fulminant liver failure associated with flutamide therapy for hirsutism , 1999, The Lancet.
[114] G. Winkler,et al. Elevated serum TNF‐α level as a link between endothelial dysfunction and insulin resistance in normotensive obese patients , 1999, Diabetic medicine : a journal of the British Diabetic Association.
[115] R. Busse,et al. Vascular endothelial growth factor up-regulates nitric oxide synthase expression in endothelial cells. , 1999, Cardiovascular research.
[116] J. Pessin,et al. Molecular Basis of Insulin-stimulated GLUT4 Vesicle Trafficking , 1999, The Journal of Biological Chemistry.
[117] M. Czech,et al. Signaling Mechanisms That Regulate Glucose Transport* , 1999, The Journal of Biological Chemistry.
[118] A. Döring,et al. C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. , 1999, Circulation.
[119] D L Rothman,et al. Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity. , 1999, The Journal of clinical investigation.
[120] G. Hotamisligil. The role of TNFalpha and TNF receptors in obesity and insulin resistance. , 1999, Journal of internal medicine.
[121] Y. Ikeda,et al. Insulin signaling is inhibited by micromolar concentrations of H(2)O(2). Evidence for a role of H(2)O(2) in tumor necrosis factor alpha-mediated insulin resistance. , 1999, The Journal of biological chemistry.
[122] R. Caldwell,et al. Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions. , 1999, Journal of the American College of Cardiology.
[123] A. Sidawy,et al. Insulin action enhancement normalizes brachial artery vasoactivity in patients with peripheral vascular disease and occult diabetes. , 1998, Journal of vascular surgery.
[124] K. Ichihara,et al. Fluvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl-CoA reductase, scavenges free radicals and inhibits lipid peroxidation in rat liver microsomes. , 1998, European journal of pharmacology.
[125] S. Hunter,et al. Captopril does not improve insulin action in essential hypertension: A double‐blind placebo‐controlled study , 1998, Journal of hypertension.
[126] S. Chatterjee. Sphingolipids in atherosclerosis and vascular biology. , 1998, Arteriosclerosis, thrombosis, and vascular biology.
[127] M. Carrier,et al. Investigation of oxidant stress and vasodepression to glyceryl trinitrate in the obese Zucker rat in vivo , 1998, British journal of pharmacology.
[128] A. Rudich,et al. Prolonged oxidative stress impairs insulin-induced GLUT4 translocation in 3T3-L1 adipocytes. , 1998, Diabetes.
[129] R. Fogari,et al. ACE inhibition but not angiotensin II antagonism reduces plasma fibrinogen and insulin resistance in overweight hypertensive patients. , 1998, Journal of cardiovascular pharmacology.
[130] Philip D. Harvey,et al. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39 , 1998, BMJ.
[131] R. Holman,et al. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .
[132] G. Garcı́a-Cardeña,et al. Biological action of leptin as an angiogenic factor. , 1998, Science.
[133] R. Holman,et al. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) , 1998, The Lancet.
[134] M. Hoenig,et al. Endothelial dysfunction precedes hypertension in diet-induced insulin resistance. , 1998, American journal of physiology. Regulatory, integrative and comparative physiology.
[135] Uk-Prospective-Diabetes-Study-Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) , 1998, The Lancet.
[136] T. Wadden,et al. Tumor Necrosis Factor-α in Sera of Obese Patients: Fall with Weight Loss , 1998 .
[137] D. Hayoz,et al. Nitric oxide synthase expression in endothelial cells exposed to mechanical forces. , 1998, Hypertension.
[138] W A Hsueh,et al. Cardiovascular risk continuum: implications of insulin resistance and diabetes. , 1998, The American journal of medicine.
[139] H. Lithell,et al. Insulin resistance in essential hypertension is related to plasma renin activity , 1998, Journal of Human Hypertension.
[140] M. Makuuchi,et al. Hypertension, hypertriglyceridemia, and impaired endothelium-dependent vascular relaxation in mice lacking insulin receptor substrate-1. , 1998, The Journal of clinical investigation.
[141] C. Tack,et al. Insulin-induced vasodilatation and endothelial function in obesity/insulin resistance. Effects of troglitazone , 1998, Diabetologia.
[142] U. Laufs,et al. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. , 1998, Circulation.
[143] H. Yki-Järvinen,et al. Insulin-induced vasodilatation: physiology or pharmacology? , 1998, Diabetologia.
[144] J. Knuuti,et al. Insulin resistance of glucose uptake in skeletal muscle cannot be ameliorated by enhancing endothelium-dependent blood flow in obesity. , 1998, The Journal of clinical investigation.
[145] T. Michel,et al. The Endothelial Nitric-oxide Synthase-Caveolin Regulatory Cycle* , 1998, The Journal of Biological Chemistry.
[146] G. D. De Keulenaer,et al. Tumour necrosis factor alpha activates a p22phox-based NADH oxidase in vascular smooth muscle. , 1998, The Biochemical journal.
[147] T. Lüscher,et al. Atherosclerosis and the two faces of endothelial nitric oxide synthase. , 1998, Circulation.
[148] L. Goodyear,et al. Exercise, glucose transport, and insulin sensitivity. , 1998, Annual review of medicine.
[149] P. Vanhoutte. Endothelial dysfunction and vascular disease. , 1998, Verhandelingen - Koninklijke Academie voor Geneeskunde van Belgie.
[150] I. Macdonald,et al. Depressor action of insulin on skeletal muscle vasculature: a novel mechanism for postprandial hypotension in the elderly. , 1998, Journal of the American College of Cardiology.
[151] T. Wadden,et al. Tumor necrosis factor-alpha in sera of obese patients: fall with weight loss. , 1998, The Journal of clinical endocrinology and metabolism.
[152] E. Block,et al. A Caveolar Complex between the Cationic Amino Acid Transporter 1 and Endothelial Nitric-oxide Synthase May Explain the “Arginine Paradox”* , 1997, The Journal of Biological Chemistry.
[153] J S Yudkin,et al. Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright © 1997 by The Endocrine Society Subcutaneous Adipose Tissue Releases Interleukin-6, But Not Tumor Necrosis Factor-�, in Vivo* , 2022 .
[154] K. Schenck-Gustafsson,et al. Transient triglyceridemia decreases vascular reactivity in young, healthy men without risk factors for coronary heart disease. , 1997, Circulation.
[155] P. Vallance,et al. Inflammatory cytokines impair endothelium-dependent dilatation in human veins in vivo. , 1997, Circulation.
[156] O. Feron,et al. Nitric oxide synthases: which, where, how, and why? , 1997, Journal of Clinical Investigation.
[157] D. Harrison,et al. Cellular and molecular mechanisms of endothelial cell dysfunction. , 1997, The Journal of clinical investigation.
[158] K. Uysal,et al. Protection from obesity-induced insulin resistance in mice lacking TNF-α function , 1997, Nature.
[159] E. Kraegen,et al. PATHOGENESIS OF THE INSULIN RESISTANCE SYNDROME (SYNDROME X) , 1997, Clinical and experimental pharmacology & physiology.
[160] S. Coppack,et al. Endothelial Dysfunction: Cause of the Insulin Resistance Syndrome , 1997, Diabetes.
[161] G. Ahlborg,et al. Exogenous endothelin-1 causes peripheral insulin resistance in healthy humans. , 1997, Acta physiologica Scandinavica.
[162] I. Laher,et al. Reactivity of mesenteric arteries from fructose hypertensive rats to endothelin-1. , 1997, American journal of hypertension.
[163] A. Mark,et al. Sympathetic and cardiorenal actions of leptin. , 1997, Hypertension.
[164] A. Baron,et al. Elevated circulating free fatty acid levels impair endothelium-dependent vasodilation. , 1997, The Journal of clinical investigation.
[165] H. Ju,et al. Direct Interaction of Endothelial Nitric-oxide Synthase and Caveolin-1 Inhibits Synthase Activity* , 1997, The Journal of Biological Chemistry.
[166] A. Marette,et al. Cytokines modulate glucose transport in skeletal muscle by inducing the expression of inducible nitric oxide synthase. , 1997, The Biochemical journal.
[167] L. M. Leeb-Lundberg,et al. Bradykinin Sequesters B2 Bradykinin Receptors and the Receptor-coupled Gα Subunits Gαq and Gαiin Caveolae in DDT1 MF-2 Smooth Muscle Cells* , 1997, The Journal of Biological Chemistry.
[168] K. Alberti,et al. The changing face of macrovascular disease in non-insulin-dependent diabetes mellitus: an epidemic in progress , 1997, The Lancet.
[169] S. O’Rahilly,et al. Congenital leptin deficiency is associated with severe early-onset obesity in humans , 1997, Nature.
[170] D. Sacks,et al. Reciprocal Regulation of Endothelial Nitric-oxide Synthase by Ca2+-Calmodulin and Caveolin* , 1997, The Journal of Biological Chemistry.
[171] J. Zierath,et al. Insulin Receptor Substrate-1 Phosphorylation and Phosphatidylinositol 3-Kinase Activity in Skeletal Muscle From NIDDM Subjects After In Vivo Insulin Stimulation , 1997, Diabetes.
[172] G. Boden. Role of Fatty Acids in the Pathogenesis of Insulin Resistance and NIDDM , 1997, Diabetes.
[173] K. Uysal,et al. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. , 1997, Nature.
[174] C. Juan,et al. Endothelin-1 induces insulin resistance in conscious rats. , 1996, Biochemical and biophysical research communications.
[175] I. Macdonald,et al. Effect of a physiological insulin infusion on the cardiovascular responses to a high fat meal: evidence supporting a role for insulin in modulating postprandial cardiovascular homoeostasis in man. , 1996, Clinical science.
[176] M. Quon,et al. Insulin-stimulated production of nitric oxide is inhibited by wortmannin. Direct measurement in vascular endothelial cells. , 1996, The Journal of clinical investigation.
[177] M. Brown,et al. A Randomised Controlled Trial of Vitamin E in Patients with Coronary Disease: The Cambridge Heart Antioxidant Study (CHAOS) , 1996 .
[178] G. Garcı́a-Cardeña,et al. Targeting of nitric oxide synthase to endothelial cell caveolae via palmitoylation: implications for nitric oxide signaling. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[179] S. Snyder,et al. Nitric oxide synthase generates superoxide and nitric oxide in arginine-depleted cells leading to peroxynitrite-mediated cellular injury. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[180] K. Petersen,et al. Mechanism of free fatty acid-induced insulin resistance in humans. , 1996, The Journal of clinical investigation.
[181] A. Baron,et al. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. , 1996, The Journal of clinical investigation.
[182] D. Harrison,et al. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. , 1996, The Journal of clinical investigation.
[183] G. Dagenais,et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. , 1996, The New England journal of medicine.
[184] D. Webb,et al. Endothelial nitric oxide production and insulin sensitivity. A physiological link with implications for pathogenesis of cardiovascular disease. , 1996, Circulation.
[185] Richard G. W. Anderson,et al. Acylation Targets Endothelial Nitric-oxide Synthase to Plasmalemmal Caveolae (*) , 1996, The Journal of Biological Chemistry.
[186] C. Ferri,et al. Circulating catecholamines and metabolic effects of captopril in NIDDM patients , 1996, Diabetes Care.
[187] L. Tartaglia,et al. Phenotypes of Mouse diabetes and Rat fatty Due to Mutations in the OB (Leptin) Receptor , 1996, Science.
[188] R. Henry,et al. The expression of TNF alpha by human muscle. Relationship to insulin resistance. , 1996, The Journal of clinical investigation.
[189] T. Lüscher,et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study. , 1996, Circulation.
[190] R. Considine,et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. , 1996, The New England journal of medicine.
[191] S. Jacob,et al. Potential Role of Bradykinin in Forearm Muscle Metabolism in Humans , 1996, Diabetes.
[192] Farris K. Timimi,et al. Vitamin C improves endothelium-dependent vasodilation in patients with non-insulin-dependent diabetes mellitus. , 1996, The Journal of clinical investigation.
[193] T. Michel,et al. Mutagenesis of palmitoylation sites in endothelial nitric oxide synthase identifies a novel motif for dual acylation and subcellular targeting. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[194] S. Bhanot,et al. Effect of chronic endothelin blockade in hyperinsulinemic hypertensive rats. , 1995, The American journal of physiology.
[195] J. Olefsky,et al. Insulin-stimulated GLUT4 Translocation Is Mediated by a Divergent Intracellular Signaling Pathway (*) , 1995, The Journal of Biological Chemistry.
[196] P. Lefebvre,et al. Short Administration of Metformin Improves Insulin Sensitivity in Android Obese Subjects with Impaired Glucose Tolerance , 1995, Diabetic medicine : a journal of the British Diabetic Association.
[197] B. Egan,et al. Oleic acid inhibits endothelial nitric oxide synthase by a protein kinase C-independent mechanism. , 1995, Hypertension.
[198] W. Sessa,et al. Cyclic strain upregulates nitric oxide synthase in cultured bovine aortic endothelial cells. , 1995, The Journal of clinical investigation.
[199] Steven L. Cohen,et al. Weight-reducing effects of the plasma protein encoded by the obese gene. , 1995, Science.
[200] K. Wu,et al. Transcriptional Induction of Endothelial Nitric Oxide Synthase Type III by Lysophosphatidylcholine (*) , 1995, The Journal of Biological Chemistry.
[201] K. Hirata,et al. Low concentration of oxidized low-density lipoprotein and lysophosphatidylcholine upregulate constitutive nitric oxide synthase mRNA expression in bovine aortic endothelial cells. , 1995, Circulation research.
[202] F. Giorgino,et al. Insulin receptor phosphorylation, insulin receptor substrate-1 phosphorylation, and phosphatidylinositol 3-kinase activity are decreased in intact skeletal muscle strips from obese subjects. , 1995, The Journal of clinical investigation.
[203] B. Spiegelman,et al. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. , 1995, The Journal of clinical investigation.
[204] W. Weintraub,et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. , 1995, The New England journal of medicine.
[205] J. Liao,et al. Oxidized Low-density Lipoprotein Decreases the Expression of Endothelial Nitric Oxide Synthase (*) , 1995, The Journal of Biological Chemistry.
[206] A. Takeshita,et al. Role of Nitric Oxide in Exercise‐Induced Vasodilation of the Forearm , 1994, Circulation.
[207] S. Kostyk,et al. Hypoxia inhibits expression of eNOS via transcriptional and posttranscriptional mechanisms. , 1994, The American journal of physiology.
[208] G. Paolisso,et al. Evidence for a relationship between oxidative stress and insulin action in non-insulin-dependent (type II) diabetic patients. , 1994, Metabolism: clinical and experimental.
[209] W. Erl,et al. Antioxidants inhibit monocyte adhesion by suppressing nuclear factor-kappa B mobilization and induction of vascular cell adhesion molecule-1 in endothelial cells stimulated to generate radicals. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.
[210] C. Juan,et al. Endothelin-1 inhibits insulin-stimulated glucose uptake in isolated rat adipocytes. , 1994, Biochemical and biophysical research communications.
[211] P. Kaminski,et al. NADH oxidoreductase is a major source of superoxide anion in bovine coronary artery endothelium. , 1994, The American journal of physiology.
[212] Z. Ba,et al. Administration of tumor necrosis factor-alpha in vivo depresses endothelium-dependent relaxation. , 1994, The American journal of physiology.
[213] T. Lüscher. The endothelium and cardiovascular disease--a complex relation. , 1994, The New England journal of medicine.
[214] W. A. Bradley,et al. Superoxide and peroxynitrite in atherosclerosis. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[215] K. Pritchard,et al. Chronic exercise in dogs increases coronary vascular nitric oxide production and endothelial cell nitric oxide synthase gene expression. , 1994, Circulation research.
[216] Brad A. Myers,et al. Challenges of HCI design and implementation , 1994, INTR.
[217] H. Adams,et al. EFFECTS OF CYTOKINES TUMOR NECROSIS FACTOR α AND INTERLEUKIN 1β ON ENDOTOXIN‐MEDIATED INHIBITION OF ENDOTHELIUM‐DERIVED RELAXING FACTOR BIOACTIVITY AND NITRIC OXIDE PRODUCTION IN VASCULAR ENDOTHELIUM , 1994, Shock.
[218] E. Forsberg,et al. Effects of ATP and bradykinin on endothelial cell Ca2+ homeostasis and formation of cGMP and prostacyclin. , 1993, The American journal of physiology.
[219] A. Morris,et al. Effects of angiotensin II on insulin sensitivity: a placebo-controlled study. , 1993, Clinical science.
[220] Y. Ebina,et al. Insulin-stimulated GLUT4 translocation is relevant to the phosphorylation of IRS-1 and the activity of PI3-kinase. , 1993, Biochemical and biophysical research communications.
[221] D. Fliser,et al. Angiotensin II enhances insulin sensitivity in healthy volunteers under euglycemic conditions , 1993, Journal of hypertension.
[222] M. Yoshizumi,et al. Tumor necrosis factor downregulates an endothelial nitric oxide synthase mRNA by shortening its half-life. , 1993, Circulation research.
[223] E. Rimm,et al. Vitamin E consumption and the risk of coronary heart disease in men. , 1993, The New England journal of medicine.
[224] T. Fujimoto. Calcium pump of the plasma membrane is localized in caveolae , 1993, Journal of Cell Biology.
[225] T. Lincoln,et al. Intracellular cyclic GMP receptor proteins , 1993, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[226] E. Levin,et al. Insulin Stimulates Production and Secretion of Endothelin From Bovine Endothelial Cells , 1993, Diabetes.
[227] R M Nerem,et al. Molecular cloning and characterization of the constitutive bovine aortic endothelial cell nitric oxide synthase. , 1992, The Journal of clinical investigation.
[228] A. Lerman,et al. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. , 1991, The New England journal of medicine.
[229] C. Kahn,et al. Structure of the insulin receptor substrate IRS-1 defines a unique signal transduction protein , 1991, Nature.
[230] J. Vane,et al. Diphenylene iodonium, an inhibitor of free radical formation, inhibits platelet aggregation. , 1991, European journal of pharmacology.
[231] H. Yki-Järvinen,et al. Effect of free fatty acids on glucose uptake and nonoxidative glycolysis across human forearm tissues in the basal state and during insulin stimulation. , 1991, The Journal of clinical endocrinology and metabolism.
[232] T. van der Poll,et al. Tumor necrosis factor mimics the metabolic response to acute infection in healthy humans. , 1991, The American journal of physiology.
[233] S. Haffner,et al. Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes? , 1990, JAMA.
[234] G. Reaven. Role of Insulin Resistance in Human Disease , 1988, Diabetes.
[235] G. Reaven. Banting lecture 1988. Role of insulin resistance in human disease. , 1988, Diabetes.
[236] Sadao Kimura,et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells , 1988, Nature.
[237] O. H. Viveros,et al. Hormonal regulation of guanosine triphosphate cyclohydrolase activity and biopterin levels in the rat adrenal cortex. , 1983, Endocrinology.
[238] C. Kahn,et al. Insulin stimulates tyrosine phosphorylation of the insulin receptor in a cell-free system , 1982, Nature.
[239] L. Hayes,et al. Angiotensin converting enzyme in cultured endothelial cells and growth medium. Relationships to enzyme from kidney and plasma. , 1981, Biochimica et biophysica acta.
[240] F. Murad,et al. Nitric oxide activates guanylate cyclase and increases guanosine 3':5'-cyclic monophosphate levels in various tissue preparations. , 1977, Proceedings of the National Academy of Sciences of the United States of America.
[241] A. Montagu. NATURAL SELECTION AND MAN'S RELATIVE HAIRLESSNESS. , 1964, JAMA.